Please login to the form below

Not currently logged in

Bristol Myers Squibb announces data on Zeposia from DAYBREAK study in MS

The data presented at ECTRIMS 2021 reinforces the efficacy and safety profile of Zeposia (ozanimod) in patients with relapsing forms of multiple sclerosis

BMS building

Bristol Myers Squibb has announced interim results from the phase 3 extension trial DAYBREAK, demonstrating the long-term efficacy and safety profile of Zeposia (ozanimod) in patients with relapsing forms of multiple sclerosis (MS).

Treatment with Zeposia demonstrated a low relapse rate and more than 70% of patients were relapse-free after four years.

Safety was consistent with prior findings and the established safety profile of Zeposia in up to five years of follow-up.

The data is being presented at the 37th Congress of the European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS) on 13-15 October 2021.

“Early and effective intervention can significantly impact physical and cognitive results over time, with low relapse rates an important indicator of patient outcomes,” said Bruce Cree, study investigator and Professor of Clinical Neurology, University of California San Francisco (UCSF) Weill Institute for Neurosciences and clinical research director, UCSF MS Center.

“The data from the DAYBREAK trial provide a clear picture of the long-term safety and efficacy profile of Zeposia, and reinforce its potential when used early in the treatment process for people living with relapsing forms of MS,” he added.

Zeposia was initially approved by the FDA for the treatment of relapsing forms of multiple sclerosis (RMS) in March 2020, while the European Commission also authorised the drug for the treatment of adult patients with relapsing remitting multiple sclerosis (RRMS) with active disease in May 2020.

“Our presentations at ECTRIMS 2021 bolster the growing body of evidence underscoring the long-term efficacy and safety of Zeposia to treat relapsing forms of MS,” said Jonathan Sadeh, head of Immunology and Fibrosis Development, Bristol Myers Squibb.

Article by
Iona Everson

14th October 2021

From: Research, Healthcare



Subscribe to our email news alerts


Add my company
Thrive Agency

We are a specialist health communication agency creating powerful and trusted content. If you’re looking for a partner to help...

Latest intelligence

Rare diseases: not so rare after all
The brave new world addressing rare diseases – a way ahead to better and more inclusive treatment...
Webinar: Evolving Patient Journeys - How to generate deeper insights in a changing healthcare landscape
Register now for part one in a series, Evolving Patient Journeys, in which our experts look at the main ways in which the patient journey has evolved in recent years....
It’s long been the case that pharma lags behind other industries when it comes to digital adoption and engagement. So, what can we learn from these other industries, and how...